Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody–Drug Conjugates
Open accessPublished version of a preprint
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Although peptide motifs represent the majority of cleavable linkers used in clinical-stage antibody-drug conjugates (ADCs), the sequences are often sensitive to cleavage by extracellular enzymes, such as elastase, which leads to systemic release of the cytotoxic payload. This action reduces the therapeutic index by causing off-target toxicities that can be dose-limiting. For example, a common side-effect of ADCs made using peptide-cleavable linkers is myelosuppression, including neutropenia. Only a few reports describe methods for optimizing peptide linkers to maintain efficient and potent tumor payload delivery while enhancing circulating stability. Herein, we address these critical limitations through the development of a tandem-cleavage linker strategy, where two sequential enzymatic cleavage events mediate payload release. We prepared dipeptides that are protected from degradation in the circulation by a sterically encumbering glucuronide moiety. Upon ADC internalization and lysosomal degradation, the monosaccharide is removed and the exposed dipeptide is degraded, which liberates the attached payload inside the target cell. We used CD79b-targeted monomethyl auristatin E (MMAE) conjugates as our model system and compared the stability, efficacy, and tolerability of ADCs made with tandem-cleavage linkers to ADCs made using standard technology with the vedotin linker. The results, where rat studies showed dramatically improved tolerability in the hematopoietic compartment, highlight the role that linker stability plays in efficacy and tolerability and also offer a means of improving an ADC's therapeutic index for improved patient outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., Raitano, A., Nadell, R., Liu, W., Lortie, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1313 · Cited by 724
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Donaghy, H. (2016) · mAbs · doi:10.1080/19420862.2016.1156829 · Cited by 495
Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
Masters, J. C., Nickens, D. J., Xuan, D., Shazer, R. L., & Amantea, M. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0520-6 · Cited by 296
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252
Site-specific chemical protein conjugation using genetically encoded aldehyde tags
Rabuka, D., Rush, J. S., deHart, G. W., Wu, P., & Bertozzi, C. R. (2012) · Nature Protocols · doi:10.1038/nprot.2012.045 · Cited by 246
Self-citationAnami, Y., Yamazaki, C. M., Xiong, W., Gui, X., Zhang, N., An, Z., & Tsuchikama, K. (2018) · Nature Communications · doi:10.1038/s41467-018-04982-3 · Cited by 226
Polatuzumab Vedotin: First Global Approval
Deeks, E. D. (2019) · Drugs · doi:10.1007/s40265-019-01175-0 · Cited by 221
Research works printed but not linked: 1
- Donaghy H., 2016, MAbs, 1
Cited by
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence
Gogia, P., Ashraf, H., Bhasin, S., & Xu, Y. (2023) · Cancers · doi:10.3390/cancers15153886 · Cited by 181
Exploration of the antibody–drug conjugate clinical landscape
Maecker, H. L., Jonnalagadda, V. S., Bhakta, S., Jammalamadaka, V., & Junutula, J. R. (2023) · mAbs · doi:10.1080/19420862.2023.2229101 · Cited by 176
Bispecific antibody drug conjugates: Making 1+1>2
Gu, Y., Wang, Z., & Wang, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.009 · Cited by 159
Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates
Balamkundu, S., & Liu, C. (2023) · Biomedicines · doi:10.3390/biomedicines11113080 · Cited by 137
Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody–Drug Conjugates
Watanabe, T., Arashida, N., Fujii, T., Shikida, N., Ito, K., Shimbo, K., Seki, T., Iwai, Y., Hirama, R., Hatada, N., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01251 · Cited by 81
Towards precision medicine using biochemically triggered cleavable conjugation
Parshad, B., Arora, S., Singh, B., Pan, Y., Tang, J., Hu, Z., & Patra, H. K. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01491-5 · Cited by 72
A Review on the Stability Challenges of Advanced Biologic Therapeutics
Sarvepalli, S., Pasika, S. R., Verma, V., Thumma, A., Bolla, S., Nukala, P. K., Butreddy, A., & Bolla, P. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050550 · Cited by 69
Benefits and challenges of antibody drug conjugates as novel form of chemotherapy
Fatima, S. W., & Khare, S. K. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.013 · Cited by 57
Ha, S. Y. Y., Anami, Y., Yamazaki, C. M., Xiong, W., Haase, C. M., Olson, S. D., Lee, J., Ueno, N. T., Zhang, N., An, Z., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0362 · Cited by 54
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Zhou, L., Lu, Y., Liu, W., Wang, S., Wang, L., Zheng, P., Zi, G., Liu, H., Liu, W., & Wei, S. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00493-8 · Cited by 51
Advancements in antibody-drug conjugates as cancer therapeutics
Fong, J. Y., Phuna, Z. X., Chong, D., Heryanto, C. M., Low, Y. S., Oh, K. C., Lee, Y., Ng, A. W. R., In, L. L. A., & Teo, M. Y. M. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.01.007 · Cited by 48
Matsuda, Y., Chang, J. R., & Mendelsohn, B. A. (2025) · ChemBioChem · doi:10.1002/cbic.202500305 · Cited by 48
Therapeutic synthetic and natural materials for immunoengineering
Slezak, A., Chang, K., Hossainy, S., Mansurov, A., Rowan, S. J., Hubbell, J. A., & Guler, M. O. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00805c · Cited by 46
Recent Advances in Peptide Linkers for Antibody-Drug Conjugates
Li, S., Guo, Y., Che, J., Dai, H., & Dong, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01982 · Cited by 42
Understanding the Toxicity Profile of Approved ADCs
Martinez, P. B., de Sá, A. L., Díaz‐Tejeiro, C., Paniagua‐Herranz, L., Sanvicente, A., López-Cade, I., Pérez‐Segura, P., Alonso‐Moreno, C., Nieto‐Jiménez, C., & Ocaña, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020258 · Cited by 35
Antibody-Drug Conjugates Containing Payloads from Marine Origin
Cheng‐Sánchez, I., Moya‐Utrera, F., Porras-Alcalá, C., López‐Romero, J. M., & Sarabia, F. (2022) · Marine Drugs · doi:10.3390/md20080494 · Cited by 33
Fujii, T., & Matsuda, Y. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2276873 · Cited by 35
Giese, M. W., Davis, P. D., Woodman, R. H., Hermanson, G. T., Pokora, A., & Vermillion, M. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00429 · Cited by 32
More than Toxins—Current Prospects in Designing the Next Generation of Antibody Drug Conjugates
Schwach, J., Abdellatif, M., & Stengl, A. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2708240 · Cited by 28
Recent Advances in Peptide Linkers of Antibody–Drug Conjugates
Yang, L., Ma, J., Liu, B., Li, Y., Ma, Y., Chen, H., & Han, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01500 · Cited by 27
Recent developments in bioconjugation: From strategies to design and clinical applications
Samieipour, F., Dianat‐Moghadam, H., & Khanahmad, H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118593 · Cited by 27
Hsu, Y., Nourzaie, O., Tocher, A. E., Nerella, K., Ermakov, G., Jung, J., Fowler, A., Wu, P., Ayesa, U., Willingham, A. T., et al. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00302 · Cited by 23
The role of hydrophilic linkers in next-generation antibody-drug conjugates
Fu, Q., Kong, X., Liu, Y., Liu, M., Huang, K., Wang, P. G., & Wu, K. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114612 · Cited by 22
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01131-0 · Cited by 20
Conilh, L., Metrangolo, V., Crescioli, S., Reichert, J. M., & Dumontet, C. (2026) · Cell · doi:10.1016/j.cell.2026.04.016 · Cited by 21
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates
Chang, H., & Shah, D. K. (2025) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-025-09978-3 · Cited by 19
Corso, A. D., Arosio, S., Arrighetti, N., Perego, P., Belvisi, L., Pignataro, L., & Gennari, C. (2021) · Chemical Communications · doi:10.1039/d1cc02895b · Cited by 19
Fang, P., You, M., Cao, Y., Feng, Q., Shi, L., Wang, J., Sun, X., Yu, D., Zhou, W., Yin, L., et al. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116318 · Cited by 17
New tactics in the design of theranostic radiotracers
Berton, C., Klingler, S., Prytuliak, S., & Holland, J. P. (2024) · npj Imaging · doi:10.1038/s44303-024-00027-1 · Cited by 17
Li, X., Patel, N. L., Kalen, J. D., & Schnermann, M. J. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202417651 · Cited by 17
Glucuronides: From biological waste to bio-nanomedical applications
Burnouf, P., Roffler, S. R., Wu, C., & Su, Y.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.031 · Cited by 16
Mohamed, H. E., Al‐Ghobashy, M. A., Abbas, S. S., & Boltia, S. A. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115249 · Cited by 14
Antibody-drug conjugates in solid tumors; new strategy for cancer therapy
Takakura, T., Shimizu, T., & Yamamoto, N. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae054 · Cited by 13
Li, Z., Zhang, J., Wu, Y., Wang, F., & Cai, T. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100081 · Cited by 12
Exploring Experimental and In Silico Approaches for Antibody–Drug Conjugates in Oncology Therapies
de Almeida, V. M., Soares, M. B. P., & Santos‐Filho, O. A. (2025) · Pharmaceuticals · doi:10.3390/ph18081198 · Cited by 12
Ochtrop, P., Jagtap, A. P., Felber, J. G., Vogt, S., Herterich, S., Mai, I., Cyprys, P., Schmitt, S., Payer, S., Kitowski, A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68605-y · Cited by 13
Nazari, M., & Rabiee, N. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202504112 · Cited by 11
Mono-amino acid linkers enable highly potent small molecule-drug conjugates by conditional release
Zheng, Y., Xu, R., Cheng, H., & Tai, W. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.020 · Cited by 11
Bruzzone, F., Barigazzi, C., Muzio, A. D., Tallarico, I., Dipasquale, A., Losurdo, A., Persico, P., Navarria, P., Pessina, F., Santoro, A., et al. (2025) · Cancers · doi:10.3390/cancers17091591 · Cited by 10
A review of targeted drug delivery with antibody-drug complexes
Sanjanwala, D., Meng, Y., Guo, Z., & Bordeau, B. M. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103732 · Cited by 9
Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives
Montalbano, M. C., Micillo, M., Deaglio, S., & Vaisitti, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27021025 · Cited by 10
Approaches to improve the translation of safety, pharmacokinetics and therapeutic index of ADCs
Huang, Q., Pilvankar, M., Dixit, R., & Yu, H. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2352600 · Cited by 9
Antibody-drug conjugates in oncology: A spotlight on overcoming resistance
Xu, X., Yu, T., & Wang, Z. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105015 · Cited by 7
Li, X., Liu, J. S., Meng, Y., Li, J., Zhao, J., Liu, D., & Zhang, X. (2026) · Pharmaceuticals · doi:10.3390/ph19020324 · Cited by 9
Nawrocka, D., Krzyścik, M. A., Służalska, K. D., & Otlewski, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210143 · Cited by 7
Development of an oxazole-based cleavable linker for peptides
Taggart, E. L., Wolff, E. J., Yanar, P., Blobe, J. P., & Shugrue, C. R. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117663 · Cited by 6
Exo-Cleavable Linkers: Enhancing Stability and Therapeutic Efficacy in Antibody-Drug Conjugates
Watanabe, T., Fujii, T., & Matsuda, Y. (2024) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.82.1117 · Cited by 5
Zhang, J., Li, W., Li, M., Wu, G., Ni, Y., Du, J., Xu, G., Duan, M., Yang, Y., Yu, X., et al. (2026) · Pharmaceutical Research · doi:10.1007/s11095-025-03953-w · Cited by 4
Mendelsohn, B. A., Gogas, K. R., Higaki, J. N., Solis, W. A., Vainshtein, I., Cheng, J. C., Park, M., Hennessy, M. A., Janson, C. M., Matsuda, Y., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-1014 · Cited by 4
Self-citationPark, S. H., Gone, G. B., Ahn, D., & Chung, S. J. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.11.004 · Cited by 4
Pillow, T. H. (2022) · Nature Chemistry · doi:10.1038/s41557-022-00993-2 · Cited by 4
Safe and Efficient Intracellular Release of SN38 via Lysosomal-Responsive SN38-G Loaded Liposomes
Burnouf, P., Su, Y.-C., & Yang, S.-H. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00722 · Cited by 2
Nanobody-drug conjugates as versatile tools for improving therapeutic potential
Banerjee, S., Mariya, A., Vangapally, S., & Paidimuddala, B. (2026) · Biochemical Engineering Journal · doi:10.1016/j.bej.2026.110072 · Cited by 2
Reprogramming the tumor immune microenvironment via antibody-drug conjugates
Xu, T., Gu, Y., & Guan, X. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642215 · Cited by 2
Electron-rich anilines as cleavable linkers for peptides
Watts, A. M., Hughes, C. J., Clausen, G. A., Yanar, P., Wolff, E. J., Rubio, P. R., Stuart, N. M., & Shugrue, C. R. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108084 · Cited by 2
Linker Design and Impact on ADC Properties
Frigerio, M., & Camper, N. (2021) · Royal Society of Chemistry eBooks · doi:10.1039/9781839165153-00071 · Cited by 2
Stimuli-responsive hydrogels for improved drug delivery
Rani, P. (2024) · Otago University Research Archive (University of Otago) · Cited by 2
In Silico Structural Analysis of Human β‐Glucuronidase for Antibody–Drug Conjugates Optimization
Canini, G., Saporiti, S., Coppa, C., Rossi, M., Centola, F., & Arcovito, A. (2025) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.70077 · Cited by 1
Exo-Linker: Unlocking Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates
Watanabe, T., & Fujii, T. (2025) · Drug Delivery System · doi:10.2745/dds.40.385 · Cited by 1
Parveen, I., Aqil, A., Sharma, S., Qadir, A., Rehman, S. A., Iqubal, A., Goh, K. W., Govind, R., Iqubal, M. K., & Kesharwani, P. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108271 · Cited by 1
Reddy, D., Jeena, V., Papo, T. R., & Ohaekenyem, E. C. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1793193 · Cited by 1
Antibody–drug conjugates: a practical review on clinical management of toxicities
Palma, A. D., Marenco, M., Mancini, S., Palaia, I., Barchiesi, G., Donato, V. D., Perniola, G., Petrella, M. C., Muzii, L., & Tomao, F. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2685304 · Cited by 1
Lee, M., & Lovly, C. M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1814095 · Cited by 1
Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives
Zheng, R., Li, S., Zhang, Z., Niu, M., Fei, J., Zhang, J., Zhou, J., Wu, K., Yi, M., & Li, T. (2026) · MedComm · doi:10.1002/mco2.70897 · Cited by 1
Antibody drug conjugate ,historical and future overview
Hammam, S. N. E. (2023) · Sohag Medical Journal · doi:10.21608/smj.2023.199323.1376 · Cited by 1
Stable, Site-Specific ADC Conjugation with SMARTag® Technology and Innovative Linker
Biologics, C., & Drake, P. (2022) · ADC Review / Journal of Antibody-drug Conjugates · doi:10.14229/jadc.2022.12.12.001 · Cited by 1
Self-citationLi, X., Patel, N. L., Kalen, J. D., & Schnermann, M. J. (2024) · Angewandte Chemie · doi:10.1002/ange.202417651 · Cited by 1
Recent Advancements in Prodrug Strategies for Targeted Cancer Therapy
Lee, C. B., Tenora, L., Ranjit, A., Tenorová, K., & Rais, R. (2025) · Progress in drug research · doi:10.1007/978-3-032-00796-4_14
Campara, B. (n.d.) · Padua Research Archive (University of Padova)
Wen, Y., Wang, W., Ma, X., Liu, H., Yin, Y., Li, R., & Jiao, Y. (2026) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2026.117435
Lehot, V. (2021) · theses.fr (ABES) · doi:10.70675/718d38b9z5733z42a0z857azc52585ec3dbc
Yang, S., Anzai, T., Tsumura, R., Fuchigami, H., Hamada, M., Yuda, J., Ikuta, K., & Yasunaga, M. (2026) · mAbs · doi:10.1080/19420862.2026.2663639
Barbosa, S. L. M., Porto, J. C. S., Pereira, J. C., Filho, J. I. A. B., Silva, F. P.-D., Sousa, J. M. D. C. E., Ferreira, J. R. D. O., Militão, G. C. G., & Ferreira, P. M. P. (2026) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2026.2664722
Antibody-Drug Conjugates in Oncology: Mechanisms, Clinical Progress, and Future Directions
Zhu, Z., Wang, S., Hong, W., Zhong, Q., Wang, W., Wang, N., Bai, M., & Ji, Z. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i2.32
Antibody-Drug Conjugates: Recent Advances
Manabe, S. (2026) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.84.514
Schinas, G., Voutsinas, P.-M., Stefanou, D., Stafylidis, C., Gkoufa, A., Ziogas, D. C., Diamantopoulos, P. T., Gogas, H., & Anastasopoulou, A. N. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01804-4
Bindman, N. A., Magunda, F., Kumar, V., Rekers, N. V., Ortiz, D. J., Trueblood, E. S., Blackburn, S., Yumul, R., Dc, A., Caspary, K., et al. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00234
Fosfaatit vasta-aine-lääkekonjugaateissa
Laaksonen, E. (2026) · Aaltodoc (Aalto University)
Challenges and approaches to the design of hydrophilic linkers for antibody-drug conjugates
Ma, X., Li, B., Ma, Y., & Lau, J. Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115314
Conditionally active antibody‒drug conjugates
Guo, C., He, Y., Lu, Y., Dun, Q., Yang, J., & Wang, Y. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.08.023
親水性リンカーと精密コンジュゲーション技術による抗体薬物複合体の高効率製造プロセス開発
WATANABE, T. (2025) · Institutional Repositories DataBase (IRDB)
Zhong, Z., Śmiłowicz, D., Joaqui‐Joaqui, M. A., Tran, P. N., Garman, L. C., Guzei, I. A., & Boros, E. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c15432
Shukla, N., Patel, M., & Snehamrutha, R. (2026) · Adolescencia e Saude · doi:10.67440/ahj.vi.2077
Li, S., Sheng, S., Fu, Z., Zhou, A., & Ning, X. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.182348
Wang, Y., & Xiao, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1928286
Yin, Y., Fan, L., Wan, R., Sun, B., Xiong, B., Zhuang, W., He, D., Bai, H., & Wang, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-03072-x
Chen, C., Guo, L., Han, X., & Deng, T. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1967108
Metadata
- Authors
- Chuprakov, S., Ogunkoya, A. O., Barfield, R. M., Bauzon, M., Hickle, C., Kim, Y. C., Yeo, D., Zhang, F., Rabuka, D., & Drake, P. M.
- Affiliations
- Catalent (United States) (US)
- Corresponding author
- Drake, Penelope M.
- ORCID
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-03-09
- Volume
- 32
- Issue
- 4
- Pages
- 746-754
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W3135311043
- Cited by
- 80
- References
- 30
- Citations by year
- 2026: 22 · 2025: 22 · 2024: 15 · 2023: 9 · 2022: 7 · 2021: 5
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Bioconjugate Chemistry (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Keywords
- antibody-drug conjugates, cleavable linkers, lysosomal degradation, payload release, CD79b, monomethyl auristatin E, in vivo stability, tolerability, neutropenia, myelosuppression, therapeutic index
- MeSH terms
- Animals, Antineoplastic Agents, Endocytosis, Female, Hydrolysis, Male, Mice, SCID, Mice, Inbred NOD, Rats, Sprague-Dawley, Immunoconjugates, Xenograft Model Antitumor Assays, Mice, Rats, CD79 Antigens, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.